Product Description
Siltuximab is recommended by international consensus as a first-line treatment for idiopathic multicentric Castleman disease on the basis of durable efficacy and safety data. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32027862/)
Mechanisms of Action: IL6 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Philippines | Poland | Portugal | Romania | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: EUSA Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: BeiGene
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Adenocarcinoma|Amyloidosis|Multiple Myeloma|Pancreatic Cancer
Phase 1: Cytokine Release Syndrome|Lymphoma, Non-Hodgkin
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CASE1424 | P1 |
Not yet recruiting |
Lymphoma, Non-Hodgkin|Cytokine Release Syndrome |
2028-09-01 |
|
| NCT03315026 | P2 |
Active, not recruiting |
Multiple Myeloma|Amyloidosis |
2025-10-01 |
|
| IRB00105616 | P2 |
Completed |
Pancreatic Cancer|Adenocarcinoma |
2023-04-05 |